· Value of Malin s stake in Immunocore is approximately €51 million · Malin retains an approximate 6% stake in Immunocore following the IPO Dublin-Ireland, 5 February 2021 : Malin Corporation plc. (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sciences companies, today notes that its investee company, Immunocore, has announced the pricing of its initial public offering (IPO) of 9.9 million American Depositary Shares (ADSs) representing 9.9 million ordinary shares at an initial public offering price of $26.00 per ADS for total gross proceeds of approximately $258 million. Immunocore also raised $15 million in a concurrent private placement. Immunocore s ADSs are expected to begin trading on The Nasdaq Global Select Market today (5 February 2021) under the ticker symbol IMCR . In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional
Immunocore Prices NASDAQ IPO The Company (LSE: SUPP) is pleased to announce that its portfolio company Immunocore Holdings plc ( Immunocore ) has announced the pricing of its initial public offering ( IPO ) of 9,935,896 American Depositary Shares ( ADSs ) representing 9,935,896 ordinary shares at an IPO price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. Immunocore also raised $15 million in a concurrent private placement. Immunocore s ADSs are expected to begin trading on The Nasdaq Global Select Market ( NASDAQ ) on February 5, 2021 under the ticker symbol IMCR. In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions.